Boeing's 787 Dreamliner and what Pharma can learn from it
The New York Times ’ recent article on Boeing’s delays getting its new 787 Dreamliner off the ground should hit close to home for many of us in the drug development industry.... Read more
Implementing adaptive trials that don't violate the sacred tenets of design
There's a great article in The Scientist this month that asks: "A once-rare type of clinical trial that violates one of the sacred tenets of trial design is taking off, but is it worth the... Read more
Real-time reporting provides real transparency to sponsors
CROs like to throw around the word “transparency,” but true visibility into what is happening during the course of a clinical trial can still be hard to come by. ClinPage’s... Read more
